Stock 603567 HEILONGJIANG ZBD PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Heilongjiang ZBD Pharmaceutical Co., Ltd.

Equities

603567

CNE100002219

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-06-05 EDT 		5-day change 1st Jan Change
12.09 CNY -2.18% Intraday chart for Heilongjiang ZBD Pharmaceutical Co., Ltd. -2.42% -0.58%
05-27 ZBD Pharma Gets China Approval for Gastric Acid Inhibiting Tablets MT
05-07 China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
ZBD Pharma Gets China Approval for Gastric Acid Inhibiting Tablets
MT
China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable
MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
ZBD Pharma Gets Nod for Tofacitinib Citrate Tablets
MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
HeiLongJiang ZBD Pharma Registers Osteoarthritis Drug
MT
Heilongjiang ZBD Pharmaceutical Co., Ltd.(XSSC:603567) added to S&P Global BMI Index
CI
Heilongjiang ZBD Pharmaceutical Co., Ltd.(XSSC:603567) added to FTSE All-World Index
CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.
CI
Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 10, 2022 has closed with 2,560,300 shares, representing 0.27% for CNY 30 million.
CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.
CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.
CI
Heilongjiang ZBD Pharmaceutical to Tie Up With Kangyue Technology on Medicine Supplies
MT
Heilongjiang ZBD Gets Approval for Traditional Medicine Product
MT
Heilongjiang ZBD’s Anti-Pulmonary Fibrosis Drug Gets U.S. Patent
MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 603567 Stock
  4. News Heilongjiang ZBD Pharmaceutical Co., Ltd.